Replies to post #99353 on Biotech Values

[marthambles]

nvs hasn't moved that much. I wonder if the news has not sunk in, or if the benefit to NVS is considered too insignificant.

[alertmeipp]

The approval will make Copaxone, M118 and thus MNTA way more valuable.

Big pharms which like to expand their generic pipeline will love to buyout MNTA even at a high premium.

[jbog]

Dew, Well 4% of Teva is about $1.9 billion. If they gave that value to mnta today we're talking $50 ish.

Won't happen unless the 3.8 mil shorts head for the door at once.